ICT-121
Solid Tumors (Targeting CD133+)
Phase 1Seeking Partner
Key Facts
Indication
Solid Tumors (Targeting CD133+)
Phase
Phase 1
Status
Seeking Partner
About Precision Life Sciences Group
Precision Lifesciences Group is a private, pre-revenue biotech firm founded in 2016, specializing in novel cell therapies for oncology. Its core technology is the Stem-to-T-Cell platform, an early-stage approach designed to engineer a patient's own stem cells to produce a continuous, controlled supply of tumor-specific killer T cells, potentially offering advantages in safety and durability over existing therapies like CAR-T. The company also holds three clinical-stage dendritic cell vaccine assets (ICT-107, ICT-121, ICT-140) for which it is seeking development partners. With operations in Boston and Nashville, the company is positioned in the competitive but high-potential field of cancer immunotherapy.
View full company profile